Trial Profile

An International Randomised Clinical Trial of Therapeutic Interventions to Assess the Effects on Outcome in Adults With Acute Myeloid Leukaemia and High Risk Myelodysplasia Undergoing Allogeneic Stem Cell Transplantation

Status: Active, no longer recruiting

Phase of Trial: Phase II/III

Latest Information Update: 15 May 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cytarabine/daunorubicin (Primary) ; Busulfan; Cytarabine; Fludarabine; Thiotepa
Indications Acute myeloid leukaemia; Myelodysplastic syndromes
Focus Therapeutic Use
Acronyms COSI

09 May 2023 Planned End Date changed from 15 Mar 2025 to 1 Mar 2025.
09 May 2023 Planned primary completion date changed from 1 Jan 2024 to 1 Mar 2025.
09 May 2023 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com